A citation-based method for searching scientific literature

Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
Times Cited: 3







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
66

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
707
66

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
66

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Diabetes Metab Syndr Obes 2020
19
66


Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Darin Ruanpeng, Patompong Ungprasert, Jutarat Sangtian, Tasma Harindhanavudhi. Diabetes Metab Res Rev 2017
54
33

Influence of ankle fracture surgery on glycemic control in patients with diabetes.
Seung Yeol Lee, Moon Seok Park, Soon-Sun Kwon, Ki Hyuk Sung, Hyun Soo Jung, Kyoung Min Lee. BMC Musculoskelet Disord 2016
5
33


Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
973
33

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
Nelson B Watts, John P Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger. J Clin Endocrinol Metab 2016
202
33


Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Silvina Gallo, Bernard Charbonnel, Allison Goldman, Harry Shi, Susan Huyck, Amanda Darekar, Brett Lauring, Steven G Terra. Diabetes Obes Metab 2019
21
33

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Pouya Saeedi, Inga Petersohn, Paraskevi Salpea, Belma Malanda, Suvi Karuranga, Nigel Unwin, Stephen Colagiuri, Leonor Guariguata, Ayesha A Motala, Katherine Ogurtsova,[...]. Diabetes Res Clin Pract 2019
510
33

Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.
Y S Zhang, W Y Weng, B C Xie, Y Meng, Y H Hao, Y M Liang, Z K Zhou. Osteoporos Int 2018
18
33

Corrigendum to "SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice" [Bone 82 (2016) 101-107].
Kathryn M Thrailkill, R C Bunn, Jeffry S Nyman, Mallikarjuna R Rettiganti, Gael E Cockrell, Elizabeth C Wahl, Sasidhar Uppuganti, Charles K Lumpkin, John L Fowlkes. Bone 2017
5
33

Is chronic hyponatremia a novel risk factor for hip fracture in the elderly?
Juan Carlos Ayus, Armando Luis Negri, Kamyar Kalantar-Zadeh, Michael L Moritz. Nephrol Dial Transplant 2012
41
33

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
170
33




Mechanisms of diabetes mellitus-induced bone fragility.
Nicola Napoli, Manju Chandran, Dominique D Pierroz, Bo Abrahamsen, Ann V Schwartz, Serge L Ferrari. Nat Rev Endocrinol 2017
256
33

Bone, body weight, and weight reduction: what are the concerns?
Sue A Shapses, Claudia S Riedt. J Nutr 2006
127
33

Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients.
Hsin-Hung Chen, Ming-Hwarng Horng, Su-Yin Yeh, I-Ching Lin, Chih-Jung Yeh, Chih-Hsin Muo, Fung-Chang Sung, Chia-Hung Kao. PLoS One 2015
15
33


Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Zhen Zhang, Yang Cao, Yujia Tao, Meng E, Jiahao Tang, Yongcui Liu, Fangping Li. Diabetes Res Clin Pract 2020
4
33

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
J Bolinder, Ö Ljunggren, L Johansson, J Wilding, A M Langkilde, C D Sjöström, J Sugg, S Parikh. Diabetes Obes Metab 2014
250
33

Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies.
A Salari-Moghaddam, O Sadeghi, A H Keshteli, B Larijani, A Esmaillzadeh. Osteoporos Int 2019
5
33


Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies.
Lili Ma, Ling Oei, Lindi Jiang, Karol Estrada, Huiyong Chen, Zhen Wang, Qiang Yu, Maria Carola Zillikens, Xin Gao, Fernando Rivadeneira. Eur J Epidemiol 2012
179
33

The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
Kathryn M Thrailkill, Jeffry S Nyman, R Clay Bunn, Sasidhar Uppuganti, Katherine L Thompson, Charles K Lumpkin, Evangelia Kalaitzoglou, John L Fowlkes. Bone 2017
29
33

Metformin; an old antidiabetic drug with new potentials in bone disorders.
Saman Bahrambeigi, Bahman Yousefi, Mahdi Rahimi, Vahid Shafiei-Irannejad. Biomed Pharmacother 2019
21
33

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
309
33

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
Zien Zhou, Meg Jardine, Vlado Perkovic, David R Matthews, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul Desai, Richard Oh, Roger Simpson,[...]. Diabetologia 2019
11
33

Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta-analysis.
Xiaoyu Li, Ting Li, Ying Cheng, Yunhong Lu, Mei Xue, Linxin Xu, Xiangyang Liu, Xiaochen Yu, Bei Sun, Liming Chen. Diabetes Metab Res Rev 2019
10
33

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
John P Bilezikian, Nelson B Watts, Keith Usiskin, David Polidori, Albert Fung, Daniel Sullivan, Norm Rosenthal. J Clin Endocrinol Metab 2016
131
33

Insulin use and fracture risk in patients with type 2 diabetes: A meta-analysis of 138,690 patients.
Yuxian Zhang, Qiuying Chen, Yuying Liang, Yuhao Dong, Xiaokai Mo, Lu Zhang, Bin Zhang. Exp Ther Med 2019
5
33

Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study.
Jenny E Blau, Viviana Bauman, Ellen M Conway, Paolo Piaggi, Mary F Walter, Elizabeth C Wright, Shanna Bernstein, Amber B Courville, Michael T Collins, Kristina I Rother,[...]. JCI Insight 2018
36
33


Type 2 Diabetes in Relation to Hip Bone Density, Area, and Bone Turnover in Swedish Men and Women: A Cross-Sectional Study.
Adam Mitchell, Tove Fall, Håkan Melhus, Alicja Wolk, Karl Michaëlsson, Liisa Byberg. Calcif Tissue Int 2018
7
33

Possible adverse effects of SGLT2 inhibitors on bone.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. Lancet Diabetes Endocrinol 2015
152
33


Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.
Wenying Yang, Ping Han, Kyung-Wan Min, Bei Wang, Traci Mansfield, Caroline T'Joen, Nayyar Iqbal, Eva Johnsson, Agata Ptaszynska. J Diabetes 2016
27
33

Counter-regulatory 'Renin-Angiotensin' System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected Patients.
Cédric Annweiler, Zhijian Cao, Yingliang Wu, Emmanuelle Faucon, Stéphanie Mouhat, Hervé Kovacic, Jean-Marc Sabatier. Infect Disord Drug Targets 2020
18
33

Metformin, neutrophils and COVID-19 infection.
Rinkoo Dalan. Diabetes Res Clin Pract 2020
3
33


Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.
Maria Mirabelli, Eusebio Chiefari, Luigi Puccio, Daniela Patrizia Foti, Antonio Brunetti. Int J Environ Res Public Health 2020
8
33

A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity.
Andy Goren, Sergio Vaño-Galván, Carlos Gustavo Wambier, John McCoy, Alba Gomez-Zubiaur, Oscar M Moreno-Arrones, Jerry Shapiro, Rodney D Sinclair, Michael H Gold, Maja Kovacevic,[...]. J Cosmet Dermatol 2020
48
33

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Wen Zhang, Yan Zhao, Fengchun Zhang, Qian Wang, Taisheng Li, Zhengyin Liu, Jinglan Wang, Yan Qin, Xuan Zhang, Xiaowei Yan,[...]. Clin Immunol 2020
432
33

The "his and hers" of the renin-angiotensin system.
Lucinda M Hilliard, Amanda K Sampson, Russell D Brown, Kate M Denton. Curr Hypertens Rep 2013
101
33

TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections.
Li Wen Shen, Hui Juan Mao, Yan Ling Wu, Yoshimasa Tanaka, Wen Zhang. Biochimie 2017
78
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.